DE60027730D1 - Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen - Google Patents
Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomenInfo
- Publication number
- DE60027730D1 DE60027730D1 DE60027730T DE60027730T DE60027730D1 DE 60027730 D1 DE60027730 D1 DE 60027730D1 DE 60027730 T DE60027730 T DE 60027730T DE 60027730 T DE60027730 T DE 60027730T DE 60027730 D1 DE60027730 D1 DE 60027730D1
- Authority
- DE
- Germany
- Prior art keywords
- cationic liposomes
- taxanes
- administration
- blood vessels
- angiogenic blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39297699A | 1999-09-09 | 1999-09-09 | |
US392976 | 1999-09-09 | ||
PCT/US2000/024579 WO2001017508A1 (en) | 1999-09-09 | 2000-09-08 | Cationic liposome delivery of taxanes to angiogenic blood vessels |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60027730D1 true DE60027730D1 (de) | 2006-06-08 |
DE60027730T2 DE60027730T2 (de) | 2007-03-29 |
Family
ID=23552795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60027730T Expired - Lifetime DE60027730T2 (de) | 1999-09-09 | 2000-09-08 | Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen |
Country Status (21)
Country | Link |
---|---|
US (1) | US20100226970A1 (de) |
EP (1) | EP1210065B1 (de) |
JP (2) | JP4848113B2 (de) |
KR (1) | KR100591767B1 (de) |
CN (1) | CN1235567C (de) |
AT (1) | ATE324867T1 (de) |
AU (1) | AU782714B2 (de) |
BR (1) | BR0013866A (de) |
CA (1) | CA2383412C (de) |
CZ (1) | CZ2002850A3 (de) |
DE (1) | DE60027730T2 (de) |
EA (1) | EA005923B1 (de) |
EE (1) | EE200200127A (de) |
ES (1) | ES2258471T3 (de) |
HK (1) | HK1046506B (de) |
HU (1) | HUP0202669A3 (de) |
IL (2) | IL148372A0 (de) |
MX (1) | MXPA02002579A (de) |
PL (1) | PL203128B1 (de) |
WO (1) | WO2001017508A1 (de) |
ZA (1) | ZA200201555B (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL366025A1 (en) * | 2000-05-03 | 2005-01-24 | Munich Biotech Ag | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
ATE345775T1 (de) * | 2001-10-03 | 2006-12-15 | Celator Pharmaceuticals Inc | Zusammensetzungen zur verabreichung von arzneimittelkombinationen |
ES2330326T3 (es) | 2002-05-24 | 2009-12-09 | Angiotech International Ag | Composiciones y metodos para recubrir implantes medicos. |
EP1374864A1 (de) * | 2002-06-26 | 2004-01-02 | Munich Biotech AG | Amphiphile, Taxane enthaltende Zusammensetzungen |
DK2286795T3 (en) | 2002-06-26 | 2017-02-06 | Syncore Biotechnology Co Ltd | PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND |
WO2004002455A1 (en) * | 2002-06-26 | 2004-01-08 | Medigene Oncology Gmbh | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
AU2004283464B8 (en) * | 2003-10-15 | 2011-04-14 | Syncore Biotechnology Co., Ltd | Method of administering cationic liposomes comprising an active drug |
JP2007517874A (ja) * | 2004-01-16 | 2007-07-05 | バーンズ−ジューイッシュ ホスピタル | 標的化アテローム性動脈硬化症治療法 |
AU2006243337B2 (en) * | 2005-05-04 | 2011-09-29 | Syncore Biotechnology Co., Ltd | Method of administering a cationic liposomal preparation comprising paclitaxel |
ES2609388T3 (es) | 2006-03-22 | 2017-04-20 | Syncore Biotechnology Co., Ltd | Tratamiento del cáncer de mama triple negativo a receptores |
ES2447465T3 (es) | 2008-03-05 | 2014-03-12 | Baxter International Inc. | Partículas de superficie modificada y métodos para la administración dirigida de fármacos |
US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
US9706903B2 (en) | 2009-06-18 | 2017-07-18 | Endochoice, Inc. | Multiple viewing elements endoscope system with modular imaging units |
DE102009032658A1 (de) * | 2009-07-09 | 2011-01-13 | Forschungszentrum Jülich GmbH | Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion |
KR101007925B1 (ko) * | 2009-10-07 | 2011-01-14 | 건일제약 주식회사 | 경구용 지질 나노입자 및 그의 제조방법 |
KR102653436B1 (ko) * | 2016-10-28 | 2024-03-29 | 르 라보레또레 쎄르비에르 | 암의 치료에서 사용하기 위한 리포솜 제형 |
KR102250123B1 (ko) | 2019-11-25 | 2021-05-10 | 주식회사 현대케피코 | 무단 변속기의 제한 목표 기어비 학습 방법 |
KR102261482B1 (ko) | 2019-12-10 | 2021-06-07 | 주식회사 현대케피코 | 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5092885A (en) * | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5192744A (en) * | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
WO1993018751A1 (en) * | 1992-03-23 | 1993-09-30 | Georgetown University | Liposome encapsulated taxol and a method of using the same |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
WO1994026254A1 (en) * | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
SI0703909T1 (en) * | 1993-06-11 | 2000-08-31 | Pharmacia & Upjohn Company | Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them |
JP4850985B2 (ja) * | 1993-07-29 | 2012-01-11 | アメリカ合衆国 | 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法 |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5641755A (en) * | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
US5837682A (en) * | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
DE19605274A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln |
AU735900B2 (en) * | 1996-03-12 | 2001-07-19 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
US5935937A (en) * | 1996-06-19 | 1999-08-10 | Fox Chase Cancer Center | Compositions and methods for inducing apoptosis |
US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
WO2000047235A2 (en) * | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
WO2003037337A1 (en) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
-
2000
- 2000-09-08 BR BR0013866-5A patent/BR0013866A/pt not_active Application Discontinuation
- 2000-09-08 ES ES00960004T patent/ES2258471T3/es not_active Expired - Lifetime
- 2000-09-08 DE DE60027730T patent/DE60027730T2/de not_active Expired - Lifetime
- 2000-09-08 CA CA002383412A patent/CA2383412C/en not_active Expired - Lifetime
- 2000-09-08 EE EEP200200127A patent/EE200200127A/xx unknown
- 2000-09-08 JP JP2001521299A patent/JP4848113B2/ja not_active Expired - Lifetime
- 2000-09-08 KR KR1020027003179A patent/KR100591767B1/ko active IP Right Grant
- 2000-09-08 WO PCT/US2000/024579 patent/WO2001017508A1/en active IP Right Grant
- 2000-09-08 PL PL354721A patent/PL203128B1/pl unknown
- 2000-09-08 MX MXPA02002579A patent/MXPA02002579A/es active IP Right Grant
- 2000-09-08 EA EA200200229A patent/EA005923B1/ru not_active IP Right Cessation
- 2000-09-08 CN CNB008141339A patent/CN1235567C/zh not_active Expired - Lifetime
- 2000-09-08 AU AU71229/00A patent/AU782714B2/en not_active Expired
- 2000-09-08 AT AT00960004T patent/ATE324867T1/de active
- 2000-09-08 CZ CZ2002850A patent/CZ2002850A3/cs unknown
- 2000-09-08 HU HU0202669A patent/HUP0202669A3/hu unknown
- 2000-09-08 IL IL14837200A patent/IL148372A0/xx active IP Right Grant
- 2000-09-08 EP EP00960004A patent/EP1210065B1/de not_active Expired - Lifetime
-
2002
- 2002-02-25 IL IL148372A patent/IL148372A/en unknown
- 2002-02-25 ZA ZA200201555A patent/ZA200201555B/en unknown
- 2002-11-12 HK HK02108184.7A patent/HK1046506B/zh not_active IP Right Cessation
-
2010
- 2010-02-10 US US12/658,620 patent/US20100226970A1/en not_active Abandoned
- 2010-07-09 JP JP2010156449A patent/JP2010280667A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60027730D1 (de) | Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen | |
NO994413D0 (no) | Kationiske lipidblandinger mÕlsökende angiogene endotelceller | |
Andrzejak et al. | Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells | |
Sugahara et al. | The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles | |
McKernan et al. | Protein kinase C: one pathway towards the eradication of latent HIV‐1 reservoirs | |
Valacchi et al. | Ozone mediators effect on “in vitro” scratch wound closure | |
BRPI0113477B8 (pt) | proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula | |
RU2011115418A (ru) | Усиление действия противораковых агентов | |
ATE229569T1 (de) | Zellzyklus regulierte repressor und dna-element | |
AR037666A1 (es) | Metodo para la identificacion de enzimas marcadores tumorales | |
AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo | |
Hur et al. | Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide | |
NO20033441L (no) | Polymerkonjugater av neubastin samt anvendelse derav | |
DE60035035D1 (de) | Injektion von autologem knochenmark in den herzmuskel | |
BR0009170A (pt) | ácidos nucléicos akt, polipeptìdeos e uso dos mesmos | |
ES2167939T3 (es) | Nuevas poliaminas, su preparacion y usos. | |
ATE372763T1 (de) | Verwendung von ascorbinsäure zur verstärkung der dermo-epidermischen bindung | |
ATE431748T1 (de) | Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren | |
DE60035687D1 (de) | Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen | |
TH72418A (th) | แทรป vegf และการใช้ทางการบำบัดของมัน | |
Kumar et al. | The treatment of cancer by influenced of alpha and beta momorcharin | |
Kotnik et al. | PULA, CROATIA June 11, 2001 | |
AR026246A1 (es) | Proteinas hcv reversibles redox con conformacion de tipo nativo | |
Zychlinsky | Necrosis and apoptosis: Cell death in the immune system. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |